E. Zhu
Impact in
-
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
-
- PARP inhibition in cancer therapy
Papers in
-
- Lymphoma Diagnosis and Treatment 2
- Genetic factors in colorectal cancer 1
-
- Ovarian cancer diagnosis and treatment 2
- Co-authors
- Gary Mason (1 shared paper)William Kevin Kelly (1 shared paper)K.N. Chi (1 shared paper)Karim Fizazi (1 shared paper)Shahneen Sandhu (1 shared paper)Daniel J. George (1 shared paper)Shinta Cheng (1 shared paper)Jason M. Summa (1 shared paper)
- Partner nations
- United StatesFranceItaly
In The Last Decade
E. Zhu
4 papers receiving 80 citations
Peers
Comparison fields: 5 of 16
- Pulmonary and Respiratory Medicine 60
- Oncology 51
- Cancer Research 11
- Genetics 6
- Molecular Biology 29
Countries citing papers authored by E. Zhu
This map shows the geographic impact of E. Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Zhu more than expected).
Fields of papers citing papers by E. Zhu
This network shows the impact of papers produced by E. Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Zhu. The network helps show where E. Zhu may publish in the future.
Co-authors
The 25 scholars most cited alongside E. Zhu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 73 | |
| 2 | 2019 | 5 | |
| 3 | Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy | 2011 | 1 |
| 4 | FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation | 2011 | 1 |
About E. Zhu
E. Zhu is a scholar working on Pathology and Forensic Medicine, Reproductive Medicine, Genetics, Pulmonary and Respiratory Medicine and Oncology, having authored 4 papers that have together received 80 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (2 papers), Ovarian cancer diagnosis and treatment (2 papers), PARP inhibition in cancer therapy (1 paper), Myeloproliferative Neoplasms: Diagnosis and Treatment (1 paper), Prostate Cancer Treatment and Research (1 paper), Integrated Circuits and Semiconductor Failure Analysis (1 paper) and Genetic factors in colorectal cancer (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (60 citations), Oncology (51 citations), Cancer Research (11 citations), Genetics (6 citations) and Molecular Biology (29 citations). E. Zhu has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Gary Mason, William Kevin Kelly, K.N. Chi, Karim Fizazi, Shahneen Sandhu, Daniel J. George, Shinta Cheng, Jason M. Summa, Eleni Efstathiou and Fred Saad. Their work appears in journals such as Annals of Oncology and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.